The long and short of telomeres and cancer association studies

Journal of the National Cancer Institute

Volumn 105, Issue 7, 2013, Pages 448-449

  Savage, Sharon A ^a   Gadalla, Shahinaz M ^a   Chanock, Stephen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; EDITORIAL; GENETIC ASSOCIATION; HEAD AND NECK CANCER; KIDNEY CARCINOMA; META ANALYSIS (TOPIC); NEOPLASM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING;

FEMALE; HUMANS; LEUKOCYTES; MALE; NEOPLASMS; TELOMERE;

EID: 84875993648     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt041     Document Type: Editorial

References (34)

1. de Lange T. How telomeres solve the end-protection problem. Science. 2009;326(5955):948-952.
2. Heaphy CM, Meeker AK. The potential utility of telomere-related markers for cancer diagnosis. J Cell Mol Med. 2011;15(6):1227-1238.
3. Ma H, Zhou Z, Wei S, et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS One. 2011;6(6):e20466.
4. Wentzensen IM, Mirabello L, Pfeiffer RM, et al. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1238-1250.
5. Baird DM. Variation at the TERT locus and predisposition for cancer. Expert Rev Mol Med. 2010;12:e16.
6. Rajaraman P, Melin BS, Wang Z, et al. Genome-wide association study of glioma and meta-analysis. Hum Genet. 2012;131(12):1877-1888.
7. Ballew BJ, Yeager M, Jacobs K, et al. Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in dyskeratosis congenita. Hum Genet. 2013 Jan 18. [Epub ahead of print]
8. Alter BP, Giri N, Savage SA, et al. Cancer in dyskeratosis congenita. Blood. 2009;113(26):6549-6557.
9. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011;2011:480-486.
10. Weicher MNBG, Cawthon RM, Freiber JJ, Tybjaerg A, Bojesen SE. Short telomere length, cancer survival, and cancer risk in 47,102 individuals. J Natl Cancer Inst. 2013.
11. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47.
12. Cawthon RM. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res. 2009;37(3):e21.
13. Aviv A, Hunt SC, Lin J, et al. Impartial comparative analysis of measurement of leukocyte telomere length/DNA content by Southern blots and qPCR. Nucleic Acids Res. 2011;39(20):e134.
14. Wu X, Amos CI, Zhu Y, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003;95(16):1211-1218. (Pubitemid 37069551)
15. Shao L, Wood CG, Zhang D, et al. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol. 2007;178(4 Pt 1):1492-1496. (Pubitemid 47368377)
16. Fitzpatrick AL, Kronmal RA, Kimura M, et al. Leukocyte telomere length and mortality in the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci. 2011;66(4):421-429.
17. Willeit P, Willeit J, Mayr A, et al. Telomere length and risk of incident cancer and cancer mortality. JAMA. 2010;304(1):69-75.
18. de Lange T. How telomeres solve the end-protection problem. Science. 2009;326(5955):948-952.
19. Heaphy CM, Meeker AK. The potential utility of telomere-related markers for cancer diagnosis. J Cell Mol Med. 2011;15(6):1227-1238.
20. Ma H, Zhou Z, Wei S, et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS One. 2011;6(6):e20466.
21. Wentzensen IM, Mirabello L, Pfeiffer RM, et al. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1238-1250.
22. Baird DM. Variation at the TERT locus and predisposition for cancer. Expert Rev Mol Med. 2010;12:e16.
23. Rajaraman P, Melin BS, Wang Z, et al. Genome-wide association study of glioma and meta-analysis. Hum Genet. 2012;131(12):1877-1888.
24. Ballew BJ, Yeager M, Jacobs K, et al. Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in dyskeratosis congenita. Hum Genet. 2013 Jan 18. [Epub ahead of print]
25. Alter BP, Giri N, Savage SA, et al. Cancer in dyskeratosis congenita. Blood. 2009;113(26):6549-6557.
26. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011;2011:480-486.
27. Weicher MNBG, Cawthon RM, Freiber JJ, Tybjaerg A, Bojesen SE. Short telomere length, cancer survival, and cancer risk in 47,102 individuals. J Natl Cancer Inst. 2013.
28. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47.
29. Cawthon RM. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res. 2009;37(3):e21.
30. Aviv A, Hunt SC, Lin J, et al. Impartial comparative analysis of measurement of leukocyte telomere length/DNA content by Southern blots and qPCR. Nucleic Acids Res. 2011;39(20):e134.
31. Wu X, Amos CI, Zhu Y, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003;95(16):1211-1218. (Pubitemid 37069551)
32. Shao L, Wood CG, Zhang D, et al. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol. 2007;178(4 Pt 1):1492-1496. (Pubitemid 47368377)
33. Fitzpatrick AL, Kronmal RA, Kimura M, et al. Leukocyte telomere length and mortality in the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci. 2011;66(4):421-429.
34. Willeit P, Willeit J, Mayr A, et al. Telomere length and risk of incident cancer and cancer mortality. JAMA. 2010;304(1):69-75.